Showing results (1-10 of 457) with videos related to
Sort By:
Pageof 46
Seminars in Cancer Biology|May 16, 2006
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathwaysGavin W Porter, Fadlo R Khuri, Haian FuCurrent Chemical Genomics|February 18, 2010
A homogenous luminescent proximity assay for 14-3-3 interactions with both phosphorylated and nonphosphorylated client peptidesYuhong Du, Fadlo R Khuri, Haian FuTrends in Pharmacological Sciences|June 4, 2013
Targeting protein-protein interactions as an anticancer strategyAndrei A Ivanov, Fadlo R Khuri, Haian FuJournal of Biomolecular Screening|May 16, 2006
Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assayYuhong Du, Shane C Masters, Fadlo R Khuri, et al.Plos One|April 3, 2014
Transcriptional regulation of YWHAZ, the gene encoding 14-3-3ζAndrea Kasinski, Xueyuan Dong, Fadlo R Khuri, et al.Seminars in Cell & Developmental Biology|October 11, 2011
14-3-3 proteins as potential therapeutic targetsJing Zhao, Cheryl L Meyerkord, Yuhong Du, et al.Cancer Biology & Therapy|October 7, 2004
The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of AktShi-Yong Sun, Zhongmei Zhou, Ruoxiang Wang, et al.Cancer Research|September 17, 2008
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activationXuerong Wang, Ping Yue, Young Ae Kim, et al.Assay and Drug Development Technologies|August 3, 2013
A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitorsYuhong Du, Robert W Fu, Bin Lou, et al.Cancer Research|August 17, 2005
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibitionShi-Yong Sun, Laura M Rosenberg, Xuerong Wang, et al.Pageof 46